

Treating patients with spinal muscular atrophy (SMA)?



Treating patients with spinal muscular atrophy (SMA)?

Consider **referring** your patient to a clinical research study:

A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy.

The investigational study drug, adimanebart (ARGX-119), is not approved by any regulatory agency for use in SMA as efficacy and safety have not been established.



Or visit
clinicaltrials.argenx.com/sparkle
for more information

